First international Competition on Runtime Verification: rules, benchmarks, tools, and final results of CRV 2014

被引：0
|
作者：
Ezio Bartocci
Yliès Falcone
Borzoo Bonakdarpour
Christian Colombo
Normann Decker
Klaus Havelund
Yogi Joshi
Felix Klaedtke
Reed Milewicz
Giles Reger
Grigore Rosu
Julien Signoles
Daniel Thoma
Eugen Zalinescu
Yi Zhang
机构：
[1] TU Wien,Inria, CNRS, Laboratoire d’Informatique de Grenoble
[2] Univ. Grenoble-Alpes,undefined
[3] University of Illinois at Urbana-Champaign,undefined
[4] McMaster University,undefined
[5] University of Malta,undefined
[6] Lübeck University,undefined
[7] Jet Propulsion Laboratory,undefined
[8] NASA,undefined
[9] University of Waterloo,undefined
[10] NEC Laboratories Europe,undefined
[11] University of Alabama at Birmingham,undefined
[12] University of Manchester,undefined
[13] CEA,undefined
[14] LIST,undefined
[15] Software Security Laboratory,undefined
[16] ETH Zurich,undefined
来源：
International Journal on Software Tools for Technology Transfer | 2019年 / 21卷
关键词：
Runtime Verification; Software competition; Monitoring; Benchmarks;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The first international Competition on Runtime Verification (CRV) was held in September 2014, in Toronto, Canada, as a satellite event of the 14th international conference on Runtime Verification (RV’14). The event was organized in three tracks: (1) offline monitoring, (2) online monitoring of C programs, and (3) online monitoring of Java programs. In this paper, we report on the phases and rules, a description of the participating teams and their submitted benchmark, the (full) results, as well as the lessons learned from the competition.
引用
收藏
页码：31 / 70
页数：39
相关论文
共 35 条
  • [31] Re: First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma with Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial Editorial Comment
    Richie, Jerome P.
    JOURNAL OF UROLOGY, 2012, 188 (01): : 115 - 116
  • [32] Final results of an international three-arm randomised phase II study evaluating oral vinorelbine plus capecitabine versus paclitaxel plus gemcitabine versus docetaxel plus gemcitabine as first-line chemotherapy in patients with metastatic breast cancer (NorCap-CA223 trial)
    Cinieri, S.
    Chan, A.
    Altundag, K.
    Tubiana-Mathieu, N.
    Barnadas, A.
    Dodyk, P.
    Lazzarelli, S.
    Botha, M.
    Villanova, G.
    Coskun, U.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S417 - S417
  • [33] Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+gastric and gastroesophageal junction (GEJ) adenocarcinoma
    Schuler, M.
    Al-Batran, S-E.
    Zvirbule, Z.
    Manikhas, G.
    Lordick, F.
    Rusyn, A.
    Vinnyk, Y.
    Vynnychenko, I.
    Fadeeva, N.
    Nechaeva, M.
    Dudov, A.
    Gotovkin, E.
    Pecheniy, A.
    Bazin, I.
    Bondarenko, I.
    Melichar, B.
    Huber, C.
    Tuereci, Oe.
    Sahin, U.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] In adults with standard-risk acute lymphoblastic leukemia (ALL) the greatest benefit is achieved from an allogeneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional Consolidation/Maintenance chemotherapy: Final results of the international ALL trial (MRC UKALL XII/ECOG E2993).
    Rowe, Jacob M.
    Buck, Georgina
    Fielding, Adele
    Tallman, Martin S.
    Burnett, Alan K.
    Chopra, Raj
    Wiernik, Peter H.
    Richards, Susan M.
    Lazarus, Hillard M.
    Foroni, Letizia
    Paietta, Elisabeth
    Litzow, Mark R.
    Marks, David
    Durrant, Jill
    Goldstone, Anthony H.
    BLOOD, 2006, 108 (11) : 5A - 5A
  • [35] In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
    Goldstone, Anthony H.
    Richards, Susan M.
    Lazarus, Hillard M.
    Tallman, Martin S.
    Buck, Georgina
    Fielding, Adele K.
    Burnett, Alan K.
    Chopra, Raj
    Wiernik, Peter H.
    Foroni, Letizia
    Paietta, Elisabeth
    Litzow, Mark R.
    Marks, David I.
    Durrant, Jill
    McMillan, Andrew
    Franklin, Ian M.
    Luger, Selina
    Ciobanu, Niculae
    Rowe, Jacob M.
    BLOOD, 2008, 111 (04) : 1827 - 1833
1234